Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 3
Submit an article Journal homepage
39
Views
7
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm

Constantin N Baxevanis Cancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital, Athens, Greece. [email protected]
Pages 275-277 | Published online: 09 Jan 2014

References

  • Mohebtash M, Tsang KY, Madan RA et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 17(22), 7164–7173 (2011).
  • Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin. Cancer Res. 17(12), 3884–3891 (2011).
  • Gulley JL, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14(10), 3060–3069 (2008).
  • Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388–1397 (2010).
  • Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59(5), 663–674 (2010).
  • Perez SA, von Hofe E, Kallinteris NL et al. A new era in anticancer peptide vaccines. Cancer 116(9), 2071–2080 (2010).
  • Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat. Rev. Clin. Oncol. 8(9), 551–561 (2011).
  • Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
  • Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099–1105 (2010).
  • Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
  • Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res. 13(13), 3776–3782 (2007).
  • Gribben JG, Ryan DP, Boyajian R et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin. Cancer Res. 11(12), 4430–4436 (2005).
  • Arlen PM, Gulley JL, Parker C et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12(4), 1260–1269 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.